Nextcure Inc (NXTC) - News Archive

Innovative Advancements in Cancer Therapy: NextCure s LNCB74 IND Application Acceptance The landscape of oncology therapeutics is on the brink of transformation with NextCure’s recent announcement. The biotechnology com...

Osteogenesis imperfecta (OI), characterized by brittle bones and high susceptibility to fractures, has long posed significant challenges in medical management. Recent advancements in therapeutic strategies, particularly...

In an era where the incessant pursuit of medical innovation remains paramount, NextCure, Inc. (Nasdaq: NXTC) has emerged as a prominent player in the biopharmaceutical landscape, particularly within the realm of oncolog...

In a significant stride towards revolutionizing cancer treatment, NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, presented compelling preclinical and clinical data at recent prestigious meeti...

Forging New Frontiers in Cancer Therapy: NextCure Unveils Promising Phase 1b Study Results at ESMO 2024 BELTSVILLE, Md. Sept. 16, 2024 In a stirring presentation, NextCure, Inc. (Nasdaq: NXTC) revealed groundbreaking cl...

BELTSVILLE, Md., May 30, 2024 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company focused on developing pioneering immunotherapies to treat cancer and other immune-related diseases, disclosed rec...

NextCure, a clinical-stage biopharmaceutical company dedicated to pioneering novel immunomedicines to combat cancer and immune-related diseases, continues to push the boundaries of scientific research. Recently, NextCur...

NextCure, Inc., a clinical-stage biopharmaceutical company, recently provided a comprehensive business update along with its full-year financial results for 2023. The company, committed to discovering and developing nov...

In a groundbreaking move, NextCure, Inc. has recently published a preclinical study in the esteemed journal Science Advances, shedding light on the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) as a T...

NextCure: A Promising Pipeline of Immunomedicines to Revolutionize Cancer TreatmentBeltsville, MD - NextCure, Inc. (Nasdaq: NXTC), a pioneering clinical-stage biopharmaceutical company focused on revolutionizing cancer...